Rompe Pecho

Description

No description information is available.

Uses and Indications

This drug is indicated for the facilitation of mucus clearance in patients experiencing excessive bronchial secretions. It helps to loosen phlegm and thin bronchial secretions, thereby aiding in the removal of bothersome mucus from the bronchial passageways.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The medication should be shaken well before use. Healthcare professionals are advised to instruct patients not to exceed 6 doses within a 24-hour period unless directed otherwise by a physician.

For dosing, the following guidelines apply:

Adults and Children 12 Years of Age and Over: Administer 10 mL (2 teaspoons) every 4 hours as needed.

Children Aged 6 to Under 12 Years: Administer 5 mL (1 teaspoon) every 4 hours as needed.

Children Under 6 Years of Age: Consultation with a physician is required prior to administration.

It is essential to adhere to these dosing recommendations to ensure safe and effective use of the medication.

Contraindications

Use is contraindicated in patients who experience a cough that persists for more than one week, tends to recur, or is accompanied by fever, rash, or persistent headache. A persistent cough may indicate a serious underlying condition that requires medical evaluation.

Warnings and Precautions

It is imperative that healthcare professionals adhere to the following warnings and precautions to ensure the safe use of this medication.

Dosage Limitations The recommended dosage should not be exceeded. Overdosing can lead to serious health complications.

Pre-existing Conditions Patients should be advised to consult a healthcare provider prior to use if they have a persistent or chronic cough, particularly in cases associated with smoking, asthma, chronic bronchitis, or emphysema. Additionally, caution is warranted if the cough is accompanied by excessive phlegm (mucus), as this may indicate an underlying condition that requires further evaluation.

Emergency Situations In the event of an accidental overdose, immediate medical assistance should be sought. Healthcare professionals should instruct patients to contact the Poison Control Center or seek emergency medical help without delay.

Monitoring and Follow-up Patients should be advised to discontinue use and consult a healthcare provider if their cough persists for more than one week, recurs, or is accompanied by additional symptoms such as fever, rash, or a persistent headache. A persistent cough may signify a serious underlying condition that necessitates further investigation and management.

Side Effects

Patients should be advised not to exceed the recommended dosage of the medication. It is important for individuals to consult a healthcare professional prior to use if they have a persistent or chronic cough, which may be associated with conditions such as smoking, asthma, chronic bronchitis, or emphysema. Additionally, caution is warranted if the cough is accompanied by excessive phlegm (mucus).

These precautions are essential to ensure the safe and effective use of the medication, minimizing the risk of adverse reactions associated with inappropriate use.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Rompe Pecho (guaifenesin). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients under 6 years of age should consult a doctor before use. For children aged 6 to under 12 years, the recommended dosage is 5 mL (1 teaspoon) every 4 hours. In contrast, adults and children 12 years of age and over may take 10 mL (2 teaspoons) every 4 hours. It is important for healthcare professionals to consider these age-specific dosing recommendations when prescribing this medication to ensure safety and efficacy in pediatric populations.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any adverse effects or changes in therapeutic response, given the lack of targeted data for this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The potential risks and benefits must be carefully weighed, as the effects on fetal outcomes and lactation are not fully established. It is essential for women of childbearing potential to seek medical advice to ensure safe use during pregnancy and lactation.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data on the excretion of this medication in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating mothers.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific overdosage information, it is essential for healthcare professionals to remain vigilant regarding the potential for overdose with this medication. In cases where an overdose is suspected, immediate medical attention should be sought.

Healthcare providers are advised to monitor patients closely for any signs or symptoms that may arise from an overdose. Common symptoms may include, but are not limited to, severe drowsiness, confusion, respiratory distress, or any other unusual clinical manifestations.

Management of an overdose should be tailored to the individual patient and may involve supportive care, symptomatic treatment, and, if applicable, the use of specific antidotes. It is crucial to consult local poison control guidelines and the product's prescribing information for detailed management protocols.

In all instances of suspected overdose, healthcare professionals should ensure that appropriate measures are taken to ensure patient safety and to mitigate any potential adverse effects.

Nonclinical Toxicology

If pregnant or breastfeeding, it is advised to consult a health professional prior to use. No specific non-teratogenic effects have been identified in the available data. Additionally, there are no detailed findings regarding nonclinical toxicology or animal pharmacology and toxicology provided in the current information.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep the medication out of reach of children to prevent accidental ingestion. In the event of an accidental overdose, patients should be instructed to seek medical help immediately or contact the Poison Control Center.

Patients should also be informed to discontinue use and consult a doctor if their cough persists for more than one week, recurs, or is accompanied by symptoms such as fever, rash, or a persistent headache. It is important to communicate that a persistent cough may indicate a serious underlying condition that requires further evaluation.

Storage and Handling

The product is supplied in a configuration that includes specific NDC numbers, which are essential for identification and inventory management. It should be stored at a controlled room temperature of 20°C to 25°C (68°F to 77°F) to maintain its efficacy.

To ensure the integrity of the product, it must be protected from light exposure. Prior to use, it is important to shake the container well to ensure proper mixing of the contents. Once opened, the product should be discarded to prevent any potential degradation or contamination.

Additional Clinical Information

The medication is administered orally. Clinicians should advise patients who are pregnant or breastfeeding to consult a health professional prior to use. No further information is available regarding laboratory tests, abuse potential, or postmarketing experiences.

Drug Information (PDF)

This file contains official product information for Rompe Pecho, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)